| Abstrakt: |
This study focuses on the preparation and evaluation of famotidine-loaded solid lipid nanoparticles (SLNs) for enhancing oral drug delivery. Famotidine, a commonly used H2 receptor antagonist for treating gastric acid-related conditions, faces challenges in oral administration due to its poor aqueous solubility and low bioavailability. To address these limitations, SLNs were formulated using a solvent emulsification-evaporation method, employing biocompatible lipids to encapsulate the drug and improve its absorption. The prepared SLNs were characterized for particle size, zeta potential, drug loading efficiency, and encapsulation efficiency. Results showed that the SLNs had an average particle size of 150 nm, a zeta potential of -25 mV, and a high drug encapsulation efficiency of 90%, ensuring stability and effective drug loading. Morphological analysis confirmed spherical nanoparticles with a smooth surface, supporting the uniformity of the formulation. In vitro release studies demonstrated a sustained drug release profile, with 60% of famotidine being released over a prolonged period, highlighting the potential of SLNs in maintaining therapeutic drug levels. Furthermore, pharmacokinetic evaluations indicated that the bioavailability of famotidine was significantly enhanced when delivered via SLNs compared to the free drug. These findings suggest that famotidine-loaded SLNs could be a promising approach for overcoming the limitations of oral famotidine delivery, offering improved bioavailability, stability, and controlled release, which could lead to better therapeutic outcomes in clinical settings. [ABSTRACT FROM AUTHOR] |
